Evidence map›Paper›PMID 16196421›Full record

ArticleLipids2005

Distribution of 22:6n-3 newly synthesized from 18:3n-3 into glycerolipid classes from tissues of rainbow trout (Oncorhynchus mykiss).

Michael V Bell, James R Dick

Abstract read
PubMed Publisher
In one paragraph

Article in Lipids, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael V BellInstitute of Aquaculture, Faculty of Natural Sciences, University of Stirling, Stirling FK9 4LA, Scotland, United Kingdom. m.v.bell@stir.ac.uk
James R Dick
University of Stirling · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The distribution of D5-22:6n-3 following ingestion of a pulse of D5-18:3n-3 was measured quantitatively by GC-negative chemical ionization MS in lipid classes from liver, cecal mucosa, and brain from rainbow trout to further our understanding of the processes determining accretion and turnover of 22:6n-3 in fish. The accretion of D5-22:6n-3 was expressed in two ways, as percent enrichment and as ng D5-22:6n-3/microg 22:6n-3/ mg D5-18:3n-3 eaten. In cecal mucosa at 2 d post-dose, PC was the most enriched lipid class followed by PE and then TAG. Enrichment fell in all lipid classes in cecal mucosa from 2 to 7 d post-dose of D5-18:3n-3. In liver, PC was also the most enriched lipid class at 2 d, but in this tissue all lipid classes were more enriched in D5-22:6n-3 by 7 d. When expressed in terms of the 22:6n-3 content of the different lipid classes, TAG became relatively less important in cecal mucosa and more important in liver. Over a time course of 3 to 35 d, the percent enrichment of D5-22:6n-3 in liver peaked at 7 d in PC, PE, PS, and PI and fell rapidly in TAG from 3 d. PC from liver was the most enriched lipid class at 3 and 7 d, and thereafter PE was the most enriched lipid class. However, TAG had the highest specific activity at all times except 7 d. In brain, the enrichment of D5-22:6n-3 was very low in all lipid classes at 3 d and increased progressively to 35 d with PC and PE similarly enriched. TAG from brain had the highest specific activity at all times. This study is the first to present quantitative information on rates of accretion and depletion of newly synthesized 22:6n-3 into the main lipid classes of fish tissues.

Indexed as

AnimalsFatty Acids, UnsaturatedGlycerolLipid MetabolismLiverOncorhynchus mykissFatty Acids, UnsaturatedGlycerol

Identifiers

PMID16196421
OpenAlexW2030671809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.